Invitrogen

MDM2 Monoclonal Antibody (IF2)

Advanced Verification

This Antibody was verified by Cell treatment to ensure that the antibody binds to the antigen stated.

14 Published Figures

39 References

View all (106) MDM2 antibodies

Datasheet

Protocols

Questions & Answers

Tech Support

Datasheet

Protocols

Questions & Answers

Tech Support

MDM2 Antibody in Immunocytochemistry (ICC/IF)

FIGURE: 1 / 20

MDM2 Antibody (33-7100) in ICC/IF

Immunofluorescence analysis of MDM2 in subconfluent U2OS cells. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.1% Triton™ X-100 for 15 minutes, and blocked with 3% BSA for 15 minutes at room temperature. The cells were probed with a MDM2 Mouse Monoclonal Antibody (Product # 33-7100) at 1.5 µg/mL for 1 hour at room temperature and then labeled with a Goat anti-Mouse IgG (H+L) Superclonal Secondary Antibody, Alexa Fluor 488 conjugate (Product # A28175) at a dilution of 1:400 for 30 minutes at room temperat... View More

MDM2 Antibody in Immunohistochemistry (Paraffin) (IHC (P))

MDM2 Antibody in Immunohistochemistry (IHC)

MDM2 Antibody in Western Blot, Proximity Ligation Assay (PLA) (WB, PLA)

Product Image Gallery

MDM2 Antibody — Figure 2 USP2 is induced by PUVA and a p53 activator, nutlin3a p53 wt CTCL cell line, MyLa2000, was subjected to PUVA a, b. or 5muM nutlin3a c-d. as shown in Methods. USP2 expression was measured by qPCR (a, c) and western blot (WB) (b, d) 2h-72h after the treatments. For qPCR, data was normalized to GAPDH and expressed as relative units (RU). The experiments were repeated 3 times, unpaired T-test was used to calculate P-value, error-bars, SD, *, P<0.05; **, P<0.01. For WB, Mdm2 and p53 protein level was also measured. beta-actin was used as internal control, and relative protein expression levels are reported below the corresponding western blot bands. Representative data was shown. {TM}

Product Details

33-7100

Applications

Tested Dilution

Publications

Western Blot (WB)

0.5-2 µg/mL

View 11 publications 11 publications

Immunohistochemistry (IHC)

View 15 publications 15 publications

Immunohistochemistry (Paraffin) (IHC (P))

1:25-1:200

View 6 publications 6 publications

Immunocytochemistry (ICC/IF)

1:25-1:200

View 1 publication 1 publication

Immunoprecipitation (IP)

1-5 µg/mL

in situ PLA (PLA)

View 1 publication 1 publication

Miscellaneous PubMed (Misc)

View 5 publications 5 publications

Product Specifications

Species Reactivity

Human

Published species

Bacteria, Guinea pig, Human, Mouse, Rat

Host/Isotype

Mouse / IgG2b, kappa

Class

Monoclonal

Type

Antibody

Clone

IF2

Immunogen

Synthetic peptide derived from the n-terminal region of human MDM2

View immunogen

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.5 mg/mL

Purification

Protein A

Storage buffer

PBS, pH 7.4, with 1mg/mL BSA, 30% glycerol

Contains

0.05% sodium azide

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2533136

Product Specific Information

This antibody recognizes the ~90 kDa (apparent MW) MDM2 protein. Also recognizes isoforms at ~57 and ~74/76 kDa. The epitope recognized by this antibody is located within amino acids 26-169 of the human protein. Positive controls: OsA-CL, MCF-7, HeLa cell lysates. HOS cells can be used for negative control. Staining of formalin fixed, paraffin embedded tissue requires heat induced epitope retrieval pretreatment.

Target Information

MDM2 is a ubiquitin ligase for p53 and plays a central role in regulation of the stability of p53. MDM2 is located on chromosome 12 on the q arm. Akt-mediated phosphorylation of MDM2 at Ser166 and Ser186 increases its interaction with p300, allowing MDM2-mediated ubiquitination and degradation of p53. Phosphorylation of MDM2 also blocks its binding to p19ARF, increasing the degradation of p53. MDM2 has also been shown to negatively regulate p53 function. MDM2 binds and inhibits transactivation role played by p53 and overexpression of MDM2 can result in the inactivation of p53 and decrease its tumor suppressor function. Another process by which MDM2 can inactivate p53 is by degrading p53 as the protein also possesses E3 ubiquitin ligase activity. Further, MDM2 plays important roles in apoptosis and cell cycle. MDM2 is over expressed in a wide range of human malignancies including soft tissue carcinomas and breast cancer. In addition to p53, MDM2 is involved in processes of cell cycle, apoptosis, and tumorigenesis through interactions with proteins that include retinoblastoma 1 and ribosomal protein L5. More than 40 different alternatively spliced transcript variants of MDM2 have been isolated from both tumor and normal tissues.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.

Molecular cancer therapeutics

Zhan Y,Zhou X,Peuget S,Singh M,Peyser BD,Fan Z,Selivanova G

33-7100 was used in Western Blotting to address the question whether RITA analogs NSC777196 and NSC782846 can induce p53-dependent apoptosis without SULT1A1-dependent DNA damage.

Fri Oct 07 00:00:00 EDT 2022

Decreased DNA Damage and Improved p53 Specificity of RITA Analogs.

Molecular cancer therapeutics

Zhan Y,Zhou X,Peuget S,Singh M,Peyser BD,Fan Z,Selivanova G

33-7100 was used in Western Blotting to address the question whether RITA analogs NSC777196 and NSC782846 can induce p53-dependent apoptosis without SULT1A1-dependent DNA damage.

Fri Oct 07 00:00:00 EDT 2022

p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors.

Cancers

Maietta I,Del Peschio F,Buonocore P,Viscusi E,Laudati S,Iannaci G,Minopoli M,Motti ML,De Falco V

33-7100 was used in Immunohistochemistry to demonstrate that p90RSK binds and phosphorylates MDM2 on serine 166 both in vitro and in vivo by kinase assay, immunoblot, and co-immunoprecipitation assay; this phosphorylation increases the stability of MDM2 which in turn binds p53, ubiquitinating it and promoting its degradation by proteasome.

Sun Dec 25 00:00:00 EST 2022

p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors.

Cancers

Maietta I,Del Peschio F,Buonocore P,Viscusi E,Laudati S,Iannaci G,Minopoli M,Motti ML,De Falco V

Sun Dec 25 00:00:00 EST 2022

The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity.

The Journal of experimental medicine

Ma S,Yan J,Barr T,Zhang J,Chen Z,Wang LS,Sun JC,Chen J,Caligiuri MA,Yu J

Published figure using MDM2 monoclonal antibody (Product # 33-7100) in Western Blot

Mon Aug 02 00:00:00 EDT 2021

The Role of TP53 in Cisplatin Resistance in Mediastinal and Testicular Germ Cell Tumors.

International journal of molecular sciences

Timmerman DM,Eleveld TF,Gillis AJM,Friedrichs CC,Hillenius S,Remmers TL,Sriram S,Looijenga LHJ

33-7100 was used in Western Blotting to suggest that TP53 mutations contribute to the cisplatin-resistant phenotype of mediastinal GCTs and, therefore, are a potential candidate for targeted treatment.

Fri Oct 29 00:00:00 EDT 2021

The Role of TP53 in Cisplatin Resistance in Mediastinal and Testicular Germ Cell Tumors.

International journal of molecular sciences

Timmerman DM,Eleveld TF,Gillis AJM,Friedrichs CC,Hillenius S,Remmers TL,Sriram S,Looijenga LHJ

Fri Oct 29 00:00:00 EDT 2021

E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration.

Developmental cell

Sladky VC,Knapp K,Soratroi C,Heppke J,Eichin F,Rocamora-Reverte L,Szabo TG,Bongiovanni L,Westendorp B,Moreno E,van Liere EA,Bakker B,Spierings DCJ,Wardenaar R,Pereyra D,Starlinger P,Schultze S,Trauner M,Stojakovic T,Scharnagl H,Fava LL,Foijer F,de Bruin A,Villunger A

33-7100 was used in Western Blotting to provide evidence that PIDDosome is a primary target to manipulate hepatocyte ploidy and proliferation rates in the regenerating liver.

Mon Feb 10 00:00:00 EST 2020

Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis - A systematic analysis of 204 cases.

Scientific reports

Trautmann M,Rehkämper J,Gevensleben H,Becker J,Wardelmann E,Hartmann W,Grünewald I,Huss S

33-7100 was used in Immunohistochemistry to show that DTF may harbor a broader mutational spectrum beyond CTNNB1 mutations, comprising targetable alterations including the herewith first reported imatinib-sensitive KIT V559D mutation in DTF.

Tue Feb 25 00:00:00 EST 2020

Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing.

Molecular cancer therapeutics

Cornillie J,Wozniak A,Li H,Wang Y,Boeckx B,Gebreyohannes YK,Wellens J,Vanleeuw U,Hompes D,Stas M,Sinnaeve F,Wafa H,Lambrechts D,Debiec-Rychter M,Sciot R,Schöffski P

33-7100 was used in Immunohistochemistry to establish and characterize histologically and molecularly stable patient-derived xenograft models from a broad variety of soft-tissue sarcomas subtypes.

Sat Jun 01 00:00:00 EDT 2019

Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.

Laboratory investigation; a journal of technical methods and pathology

Kim YJ,Kim M,Park HK,Yu DB,Jung K,Song K,Choi YL

33-7100 was used in Immunocytochemistry-immunoflourescence to examine whether MDM2 and/or CDK4 cause well-differentiated liposarcoma (WDLPS)/dedifferentiated liposarcoma (DDLPS).

Sun Sep 01 00:00:00 EDT 2019

FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer.

Cancers

Pellegrino M,Rizza P,Donà A,Nigro A,Ricci E,Fiorillo M,Perrotta I,Lanzino M,Giordano C,Bonofiglio D,Bruno R,Sotgia F,Lisanti MP,Sisci D,Morelli C

Published figure using MDM2 monoclonal antibody (Product # 33-7100) in Western Blot

Mon Nov 25 00:00:00 EST 2019

FoxO3a as a Positive Prognostic Marker and a Therapeutic Target in Tamoxifen-Resistant Breast Cancer.

Cancers

Pellegrino M,Rizza P,Donà A,Nigro A,Ricci E,Fiorillo M,Perrotta I,Lanzino M,Giordano C,Bonofiglio D,Bruno R,Sotgia F,Lisanti MP,Sisci D,Morelli C

Published figure using MDM2 monoclonal antibody (Product # 33-7100) in Western Blot

Mon Nov 25 00:00:00 EST 2019

A rare case of atypical/anaplastic meningioma with MDM2 amplification.

Rare tumors

Wylleman R,Debiec-Rychter M,Sciot R

Published figure using MDM2 monoclonal antibody (Product # 33-7100) in Immunohistochemistry

Wed Sep 30 00:00:00 EDT 2020

A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent.

Cancers

Berthier S,Larrouquère L,Champelovier P,Col E,Lefebvre C,Cottet-Rouselle C,Arnaud J,Garrel C,Laporte F,Boutonnat J,Faure P,Hazane-Puch F

33-7100 was used in Immunohistochemistry to establish a new human glioblastoma multiform cell line from the cerebro-spinal fluid of a patient affected by GBM with leptomeningeal metastasis.

Fri Dec 21 00:00:00 EST 2018

RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.

Oncotarget

Gottlieb A,Althoff K,Grunewald L,Thor T,Odersky A,Schulte M,Deubzer HE,Heukamp L,Eggert A,Schramm A,Schulte JH,Künkele A

Published figure using MDM2 monoclonal antibody (Product # 33-7100) in Western Blot

Tue Apr 25 00:00:00 EDT 2017

Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy.

PloS one

Yang SH,Lee JC,Guo JC,Kuo SH,Tien YW,Kuo TC,Cheng AL,Yeh KH

33-7100 was used in Immunohistochemistry to evaluate the prognostic roles of murine double minute 2 (MDM2) and p53 in pancreatic cancer patients treated with gemcitabine-based chemotherapy.

Mon Oct 02 00:00:00 EDT 2017

Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy.

PloS one

Yang SH,Lee JC,Guo JC,Kuo SH,Tien YW,Kuo TC,Cheng AL,Yeh KH

33-7100 was used in Immunohistochemistry to evaluate the prognostic roles of murine double minute 2 (MDM2) and p53 in pancreatic cancer patients treated with gemcitabine-based chemotherapy.

Mon Oct 02 00:00:00 EDT 2017

Oridonin synergizes with Nutlin-3 in osteosarcoma cells by modulating the levels of multiple Bcl-2 family proteins.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Wang XH,Zhang SF,Bao JT,Liu FY

33-7100 was used in Western Blotting to suggest that the combined treatment of Nutlin-3 plus Oridonin may offer a novel therapeutic strategy for osteosarcoma.

Thu Jun 01 00:00:00 EDT 2017

Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2.

Cell death & disease

Ren Z,Aerts JL,Vandenplas H,Wang JA,Gorbenko O,Chen JP,Giron P,Heirman C,Goyvaerts C,Zacksenhaus E,Minden MD,Stambolic V,Breckpot K,De Grève J

Published figure using MDM2 monoclonal antibody (Product # 33-7100) in Western Blot

Thu Dec 22 00:00:00 EST 2016

Ubiquitin-specific protease 2 decreases p53-dependent apoptosis in cutaneous T-cell lymphoma.

Oncotarget

Wei T,Biskup E,Gjerdrum LM,Niazi O,Ødum N,Gniadecki R

337100 was used in western blot to find that USP2 stabilizes Mdm2 which antagonizes p53 activity

Tue Jul 26 00:00:00 EDT 2016

MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.

Oncotarget

Grünewald I,Trautmann M,Busch A,Bauer L,Huss S,Schweinshaupt P,Vollbrecht C,Odenthal M,Quaas A,Büttner R,Meyer MF,Beutner D,Hüttenbrink KB,Wardelmann E,Stenner M,Hartmann W

33-7100 was used in Immunohistochemistry to analyse the mutational status, genomic amplification and protein expression in a range of oncogenes in adenoma salivary duct carcinoma.

Tue Nov 15 00:00:00 EST 2016

Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Saâda-Bouzid E,Burel-Vandenbos F,Ranchère-Vince D,Birtwisle-Peyrottes I,Chetaille B,Bouvier C,Château MC,Peoc'h M,Battistella M,Bazin A,Gal J,Michiels JF,Coindre JM,Pedeutour F,Bianchini L

33-7100 was used in immunohistochemistry to investigate the frequency and contribution of HMGA2, CDK4, and JUN to dedifferentiated liposarcomas and atypical lipomatous tumors/well-differentiated liposarcomas.

Sun Nov 01 00:00:00 EDT 2015

Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report.

Applied immunohistochemistry & molecular morphology : AIMM

Weingertner N,Neuville A,Chibon F,Ray-Coquard I,Marcellin L,Ghnassia JP

33-7100 was used in immunohistochemistry - paraffin section to characterize a primary myxoid liposarcoma with chondroid and osseous components

Sun Mar 01 00:00:00 EST 2015

Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling.

PloS one

Qiu HB,Zhang LY,Ren C,Zeng ZL,Wu WJ,Luo HY,Zhou ZW,Xu RH

Published figure using MDM2 monoclonal antibody (Product # 33-7100) in Western Blot

Mon Sep 30 00:00:00 EDT 2013

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.

Neuro-oncology

Künkele A,De Preter K,Heukamp L,Thor T,Pajtler KW,Hartmann W,Mittelbronn M,Grotzer MA,Deubzer HE,Speleman F,Schramm A,Eggert A,Schulte JH

33-7100 was used in Western Blotting to suggest that inhibition of the MDM2-p53 interaction with nutlin-3 is a promising therapeutic option for medulloblastomas with functional p53 that should be further evaluated in clinical trials.

Sun Jul 01 00:00:00 EDT 2012

MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype.

The American journal of surgical pathology

Yoshida A,Ushiku T,Motoi T,Beppu Y,Fukayama M,Tsuda H,Shibata T

Thu Mar 01 00:00:00 EST 2012

MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Dujardin F,Binh MB,Bouvier C,Gomez-Brouchet A,Larousserie F,Muret Ad,Louis-Brennetot C,Aurias A,Coindre JM,Guillou L,Pedeutour F,Duval H,Collin C,de Pinieux G

33-7100 was used in immunohistochemistry to examine expression of MDM2-CDK4 in low-grade osteosarcomas and fibrous or fibro-osseous lesions of the bone or paraosseous soft tissue.

Sun May 01 00:00:00 EDT 2011

Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Yoshida A,Ushiku T,Motoi T,Shibata T,Beppu Y,Fukayama M,Tsuda H

33-7100 was used in immunohistochemistry - paraffin section to explore the use of MDM2 and CDK4 for the histological diagnosis of low-grade osteosarcoma

Wed Sep 01 00:00:00 EDT 2010

Well-differentiated liposarcoma with low-grade osteosarcomatous component: an underrecognized variant.

The American journal of surgical pathology

Yoshida A,Ushiku T,Motoi T,Shibata T,Fukayama M,Tsuda H

33-7100 was used in immunohistochemistry - paraffin section to use 9 cases of well-differentiated/dedifferentiated liposarcoma to characterize unappreciated features

Wed Sep 01 00:00:00 EDT 2010

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Horvai AE,DeVries S,Roy R,O'Donnell RJ,Waldman F

33-7100 was used in immunohistochemistry - paraffin section to report genetic changes in dedifferentiated liposarcomas

Sun Nov 01 00:00:00 EDT 2009

Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Weaver J,Goldblum JR,Turner S,Tubbs RR,Wang WL,Lazar AJ,Rubin BP

Thu Jan 01 00:00:00 EST 2009

Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Weaver J,Goldblum JR,Turner S,Tubbs RR,Wang WL,Lazar AJ,Rubin BP

Thu Jan 01 00:00:00 EST 2009

Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Weaver J,Goldblum JR,Turner S,Tubbs RR,Wang WL,Lazar AJ,Rubin BP

Thu Jan 01 00:00:00 EST 2009

Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Weaver J,Goldblum JR,Turner S,Tubbs RR,Wang WL,Lazar AJ,Rubin BP

Thu Jan 01 00:00:00 EST 2009

Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Daugaard S,Christensen LH,Høgdall E

33-7100 was used in immunohistochemistry - paraffin section to identify immunohistochemical markers to aid chondroid tumor diagnosis

Wed Jul 01 00:00:00 EDT 2009

Lipoleiomyosarcoma of the rectosigmoid colon: a unique site for a rare variant of liposarcoma.

American journal of clinical oncology

Nahal A,Meterissian S

33-7100 was used in immunohistochemistry to discuss a rare presentation of a lipoleiomyosarcoma and review the method of pathologic diagnosis

Sat Aug 01 00:00:00 EDT 2009

Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Horvai AE,Schaefer JT,Nakakura EK,O'Donnell RJ

33-7100 was used in immunohistochemistry - paraffin section to assess if immunostaining for PPAR-gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas

Thu May 01 00:00:00 EDT 2008

Sporadic desmoid tumor. An exceptional cause of cystic pancreatic lesion.

JOP : Journal of the pancreas

Amiot A,Dokmak S,Sauvanet A,Vilgrain V,Bringuier PP,Scoazec JY,Sastre X,Ruszniewski P,Bedossa P,Couvelard A

33-7100 was used in immunohistochemistry to discuss the properties of desmoid tumors

Thu May 08 00:00:00 EDT 2008

Reproducibility of MDM2 and CDK4 staining in soft tissue tumors.

American journal of clinical pathology

Binh MB,Garau XS,Guillou L,Aurias A,Coindre JM

Mon May 01 00:00:00 EDT 2006

alpha-fetoprotein expression in a dedifferentiated liposarcoma.

Virchows Archiv : an international journal of pathology

Bosco M,Allia E,Coindre JM,Odasso C,Pagani A,Pacchioni D

33-7100 was used in immunohistochemistry - paraffin section to present a unique case of relapsing retroperitoneal dedifferentiated liposarcoma with alpha-fetoprotein ectopic production

Sat Apr 01 00:00:00 EST 2006

Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Wang YC,Lin RK,Tan YH,Chen JT,Chen CY,Wang YC

Sat Jan 01 00:00:00 EST 2005

MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610.

Cancer

Khor LY,Desilvio M,Al-Saleem T,Hammond ME,Grignon DJ,Sause W,Pilepich M,Okunieff P,Sandler H,Pollack A

Thu Sep 01 00:00:00 EDT 2005

Palmar atypical lipomatous tumour with spindle cell features (well-differentiated spindle cell liposarcoma): a rare neoplasm arising in an unusual anatomical location.

Virchows Archiv : an international journal of pathology

Mentzel T,Toennissen J,Rütten A,Schaller J

33-7100 was used in immunohistochemistry - paraffin section to present the case of a patient with a rare atypical lipomatous tumor with spindle cell features

Tue Mar 01 00:00:00 EST 2005

Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity.

The Journal of pathology

Coindre JM,Hostein I,Maire G,Derré J,Guillou L,Leroux A,Ghnassia JP,Collin F,Pedeutour F,Aurias A

33-7100 was used in immunohistochemistry (frozen) to characterize dedifferentiated liposarcomas with an inflammatory malignant fibrous histiocytoma component.

Thu Jul 01 00:00:00 EDT 2004

Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Coindre JM,Mariani O,Chibon F,Mairal A,De Saint Aubain Somerhausen N,Favre-Guillevin E,Bui NB,Stoeckle E,Hostein I,Aurias A

33-7100 was used in immunohistochemistry (paraffin) to report that most so-called malignant fibrous histiocytomas from the retroperitoneum are dedifferentiated liposarcoma.

Sat Mar 01 00:00:00 EST 2003

Bioinformatics

Protein Aliases: Double minute 2 protein; double minute 2, human homolog of; p53-binding protein; E3 ubiquitin-protein ligase Mdm2; Hdm2; HGNC:6973; human homolog of; MDM2 oncogene, E3 ubiquitin protein ligase; MDM2 proto-oncogene, E3 ubiquitin protein ligase; MDM2 variant FB28; Mdm2, p53 E3 ubiquitin protein ligase homolog; Mdm2, transformed 3T3 cell double minute 2, p53 binding protein; MGC5370; MGC71221; Oncoprotein Mdm2; OTTHUMP00000183490; OTTHUMP00000183492; OTTHUMP00000183494; OTTHUMP00000183495; OTTHUMP00000183496; OTTHUMP00000183497; p53-binding protein Mdm2; RING-type E3 ubiquitin transferase Mdm2

View more View less

Gene Aliases: ACTFS; hdm2; HDMX; MDM2

View more View less

UniProt ID: (Human) Q00987

View more View less

Entrez Gene ID: (Human) 4193

View more View less

Function(s)

p53 binding ubiquitin-protein transferase activity protein binding zinc ion binding ligase activity SUMO transferase activity enzyme binding ubiquitin protein ligase binding identical protein binding peroxisome proliferator activated receptor binding ubiquitin protein ligase activity scaffold protein binding chromatin/chromatin-binding, or -regulatory protein

Process(es)

negative regulation of transcription from RNA polymerase II promoter blood vessel development blood vessel remodeling regulation of heart rate atrioventricular valve morphogenesis endocardial cushion morphogenesis ventricular septum development atrial septum development protein complex assembly DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest traversing start control point of mitotic cell cycle positive regulation of cell proliferation response to toxic substance response to carbohydrate response to iron ion positive regulation of gene expression negative regulation of protein processing viral process protein ubiquitination protein sumoylation peptidyl-lysine modification protein destabilization response to magnesium ion positive regulation of proteasomal ubiquitin-dependent protein catabolic process protein localization to nucleus regulation of protein catabolic process response to cocaine response to drug protein ubiquitination involved in ubiquitin-dependent protein catabolic process negative regulation of cysteine-type endopeptidase activity involved in apoptotic process response to morphine negative regulation of DNA damage response, signal transduction by p53 class mediator establishment of protein localization response to ether negative regulation of transcription, DNA-templated positive regulation of mitotic cell cycle response to antibiotic positive regulation of protein export from nucleus response to steroid hormone cardiac septum morphogenesis cellular response to hydrogen peroxide negative regulation of cell cycle arrest cellular response to antibiotic cellular response to vitamin B1 cellular response to alkaloid cellular response to growth factor stimulus cellular response to peptide hormone stimulus cellular response to estrogen stimulus cellular response to hypoxia cellular response to UV-C regulation of signal transduction by p53 class mediator negative regulation of signal transduction by p53 class mediator

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

MDM2 Monoclonal Antibody (IF2)

MDM2 Antibody (33-7100) in ICC/IF

Product Details

33-7100

Western Blot (WB)

Immunohistochemistry (IHC)

Immunohistochemistry (Paraffin) (IHC (P))

Immunocytochemistry (ICC/IF)

Immunoprecipitation (IP)

in situ PLA (PLA)

Miscellaneous PubMed (Misc)

Species Reactivity

Published species

Host/Isotype

Class

Type

Clone

Immunogen

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Product Specific Information

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!